Sign Out
Patients who have shown hypersensitivity to loratadine and pseudoephedrine or idiosyncrasy to their components including the metabolite descarboethoxy-loratadine, to adrenergic agents or to other drugs of similar chemical structure.
Patients receiving monoamine oxidase (MAO) inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow-angle glaucoma, urinary retention, hypertension, severe coronary artery disease and hyperthyroidism.
